- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
Amyloid-Beta A4 Antibody (APP)Rabbit Monoclonal Antibody
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AJ1042b | 100ul 400 ul | 2-3 days | $ 315.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
Amyloid-Beta A4 Antibody (APP) - Product info | |
| Application | IHC, WB
|
| Primary Accession | P05067 |
| Reactivity | Human, Mouse, Rat |
| Clone Names | Y188 |
| Calculated MW | 86943 Da |
| Gene ID 351 | |
| Other Names APP, A4, AD1, C31, Gamma-CTF(50);Amyloid intracellular domain 50 | |
| Target/Specificity A synthetic peptide corresponding to residues in the NPXY motif of human Amyloid Beta A4 precusor (APP) was used as immunogen. This antibody specifically recognizes APP and its isoforms. It will not recognize either of the two Amyloid Beta Protein ( A?4 ) variants, A?1 -40 or A?1 -42. | |
| Dilution IHC~~1:250~500 WB~~1:1000~10000 | |
| Format 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions Amyloid-Beta A4 Antibody (APP) is for research use only and not for use in diagnostic or therapeutic procedures. | |
Amyloid-Beta A4 Antibody (APP) - Protein Information | |
| Name APP | |
| Synonyms A4, AD1 | |
| Function Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER- dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1 Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain (By similarity) N-APP binds TNFRSF21 triggering caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6) | |
| Cellular Location Membrane; Single-pass type I membrane protein. Membrane, clathrin-coated pit. Note=Cell surface protein that rapidly becomes internalized via clathrin-coated pits. During maturation, the immature APP (N-glycosylated in the endoplasmic reticulum) moves to the Golgi complex where complete maturation occurs (O-glycosylated and sulfated). After alpha-secretase cleavage, soluble APP is released into the extracellular space and the C-terminal is internalized to endosomes and lysosomes. Some APP accumulates in secretory transport vesicles leaving the late Golgi compartment and returns to the cell surface. Gamma-CTF(59) peptide is located to both the cytoplasm and nuclei of neurons. It can be translocated to the nucleus through association with APBB1 (Fe65). Beta-APP42 associates with FRPL1 at the cell surface and the complex is then rapidly internalized. APP sorts to the basolateral surface in epithelial cells. During neuronal differentiation, the Thr-743 phosphorylated form is located mainly in growth cones, moderately in neurites and sparingly in the cell body. Casein kinase phosphorylation can occur either at the cell surface or within a post-Golgi compartment. Associates with GPC1 in perinuclear compartments | |
| Tissue Location Expressed in all fetal tissues examined with highest levels in brain, kidney, heart and spleen. Weak expression in liver. In adult brain, highest expression found in the frontal lobe of the cortex and in the anterior perisylvian cortex- opercular gyri. Moderate expression in the cerebellar cortex, the posterior perisylvian cortex-opercular gyri and the temporal associated cortex. Weak expression found in the striate, extra- striate and motor cortices. Expressed in cerebrospinal fluid, and plasma. Isoform APP695 is the predominant form in neuronal tissue, isoform APP751 and isoform APP770 are widely expressed in non- neuronal cells. Isoform APP751 is the most abundant form in T- lymphocytes. Appican is expressed in astrocytes | |
Amyloid-Beta A4 Antibody (APP) - Related products
AP3025a: Phospho-APP-S198 Antibody
AP3026a: Phospho-APP-S730 Antibody
AP3027a: Phospho-APP-Y757 Antibody
AP6306a: APP Antibody (N-term)
AP6306b: APP Antibody (C-term)
AP6306c: APP Antibody (C-term D672)
BP3025a: Phospho-APP-S198 Antibody Blocking Peptide
BP3026a: Phospho-APP-S730 Antibody Blocking Peptide
BP3027a: Phospho-APP-Y757 Antibody Blocking Peptide
BP6306a: APP Antibody (N-term) Blocking Peptide
BP6306b: APP Antibody (C-term) Blocking Peptide
BP6306c: APP Antibody (C-term D672) Blocking Peptide
BP9053a: APP-pY756 Antibody Blocking Peptide
Amyloid-Beta A4 Antibody (APP) - Application data
-
Staining of various paraffin-embedded human tissue samples using anti-Amyloid Beta A4 precursor RabMAb (Cat. #AJ1042b). Human breast showed negative staining. Tissues were stained in parallel on the same Normal Tissue Array.
-
B. Staining of various paraffin-embedded human tissue samples using anti-Amyloid Beta A4 precursor RabMAb (Cat. #AJ1042b). Human brain tissue showed positive immunohistochemical staining for Amyloid Beta A4 precursor. Tissues were stained in parallel on the same Normal Tissue Array.
-
Staining of various paraffin-embedded human tissue samples using anti-Amyloid Beta A4 precursor RabMAb (Cat. #AJ1042b). Skeletal muscle showed negative staining. Tissues were stained in parallel on the same Normal Tissue Array.
-
Staining of various paraffin-embedded human tissue samples using anti-Amyloid Beta A4 precursor RabMAb (Cat. #AJ1042b). Liver showed negative staining. Tissues were stained in parallel on the same Normal Tissue Array.
-
A. Western blot analysis on Hela cell lysate using anti- Amyloid Beta A4 precusor RabMAb (Cat. #AJ1042b), dilution 1:20,000
Amyloid-Beta A4 Antibody (APP) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Alzheimer's disease (AD) is characterized by the presence of senile plaques in the brain and blood vessel walls. Amyloid Beta A4 (A?4) protein has been found to be the principal constituent of senile plaques of ADs patients (1-2). The amyloid beta-protein precursor (APP) is proteolytically cleaved to generate the 4 kDa A?4 protein. Two variants of A?4 can be detected; A?1-40 short-tailed and A?1-42 long-tailed (3-4).
REFERENCES
1. Glenner, G. G., Wong, C. W. (1984) Biochem. Biophys. Res. Commun. 120, 885-890
2. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B., Beyreuther, K. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 4245-4249
3. Dovey, H. F., Suomesaari-Chrysler, S., Lieberburg, I., Sinha, S., and Kiem, P. S. (1993) NeuroReport 4, 1039-1042
4. Vigo-Pelfrey, C., Lee, D., Keim, P., Lieberburg, I., Schenk, D. B. (1993) J. Neurochem. 61, 1965-1968
